OS Therapies, Inc. (OSTX) said the European Medicines Agency has initiated a rolling review of its Conditional Marketing Authorization (CMA) application for OST-HER2, an immunotherapy designed to prevent or delay recurrence in patients with fully resected pulmonary metastatic osteosarcoma. The company called the regulatory progress a major step toward potential early market access in Europe.
OS Therapies Inc. (OSTX) is stepping into the spotlight in Q4 2025, propelled by a pivotal regulatory update that could redefine its path to market. Company Overview OS Therapies is a clinical-stage biopharmaceutical company headquartered in Grasonville, Maryland, focused on developing innovative...
OS Therapies issued a regulatory update on its plans for filing marketing authorizations in the United States and United Kingdom for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. The company has updated its regulatory filing sequence to prioritize...
Shares of OS Therapies Inc. (OSTX) were gaining around 12% in the pre-market activity after the company announced Thursday that it was granted an End of Phase 2 Meeting by the United States Food & Drug Administration. The meeting would review the OST-HER2 program in the prevention or delay of recurrent,...
OS Therapies Inc. (OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, is scheduled to make a presentation at the MIB Agents Factor Osteosarcoma Conference on June 28, 2025.
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.